Getting to the surface: A link between tumor antigen discovery and natural presentation of peptide-MHC complexes

Clinical Cancer Research

Volumn 11, Issue 15, 2005, Pages 5333-5336

  Clark, Carolyn E ^a   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELOBLASTIN; PROSTATE SPECIFIC ANTIGEN; SURVIVIN; T LYMPHOCYTE RECEPTOR; TELOMERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WILMS TUMOR ANTIGEN;

ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CELL ISOLATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NOTE; PRIORITY JOURNAL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL MEMBRANE; CELL PROLIFERATION; EPITOPES; GENES, MHC CLASS I; HUMANS; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; T-LYMPHOCYTES;

EID: 23044492764     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1057     Document Type: Note

References (23)

1. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005;54:187-207.
2. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
3. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
4. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class IMHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-3.
5. + cytotoxic T cell with apparent high affinity. J Immunol 1997;158:5797-804.
6. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
7. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
8. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001;22:516-23.
9. Miyahara Y, Naota H, Wang L, et al. Determination of cellularly processed HLA-A2402 restricted novel CTL epitopes derived from two cancer-germline genes, MAGE-A4 and SAGE. Clin Cancer Res 2005;11:5581-89.
10. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004;199:251-63.
11. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004;103:2046-54.
12. Schirle M, Keilholz W, Weber B, et al. Identification of tumor-associated MHC class I ligands by a novel Tcell-independent approach. Eur J Immunol 2000;30:2216-25.
13. Maecker B, Sherr DH, Vonderheide RH, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102:3287-94.
14. Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad Sci U S A 2000;97:7969-74.
15. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005;23:349-54.
16. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991;352:67-70.
17. + CTL Mol Immunol 1994;31:1285-93.
18. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995;154:567-76.
19. Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol 2004;5:524-30.
20. Gross DA, Graff-Dubois S, Dpolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004;113:425-33.
21. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997;57:4570-7.
22. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001;98:8809-14.
23. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICDM alone and sequentially with vaccinia-CEA(6D)-TRICDM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-31.